1. Home
  2. Products
  3. Customized ADCs
  4. LTA
  5. Anti-LTA (Pateclizumab)-MC-MMAF ADC

Anti-LTA (Pateclizumab)-MC-MMAF ADC (CAT#: ADC-W-1534)

This ADC product is comprised of an anti-LTA monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • LTA
  • Alternative Names
  • LTA; lymphotoxin alpha (TNF superfamily, member 1); TNFB; lymphotoxin-alpha; LT; TNFSF1; LT-alpha; TNF-beta; tumor necrosis factor beta; tumor necrosis factor ligand superfamily member 1;
  • Target Entrez Gene ID
  • 4049
  • Overview
  • The encoded protein, a member of the tumor necrosis factor family, is a cytokine produced by lymphocytes. The protein is highly inducible, secreted, and forms heterotrimers with lymphotoxin-beta which anchor lymphotoxin-alpha to the cell surface. This protein also mediates a large variety of inflammatory, immunostimulatory, and antiviral responses, is involved in the formation of secondary lymphoid organs during development and plays a role in apoptosis. Genetic variations in this gene are associated with susceptibility to leprosy type 4, myocardial infarction, non-Hodgkin's lymphoma, and psoriatic arthritis. Alternatively spliced transcript variants have been observed for this gene.
  • Overview
  • Humanized Anti-LTA IgG1-kappa antibody, Pateclizumab
  • Generic name
  • Pateclizumab
  • Host animal
  • Mouse
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-1534. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-1536 Anti-LTA (Pateclizumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-1532 Anti-LTA (Pateclizumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-1533 Anti-LTA (Pateclizumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1537 Anti-LTA (Pateclizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1535 Anti-LTA (Pateclizumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
CAT# Product Name Linker Payload
ADC-W-2612 Anti-MS4A1 (Rituximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-491 Anti-TNFRSF17-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-322 Anti-CD19-Mc-MMAF ADC-1 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-517 Anti-TM4SF1-Mc-LP2 ADC-1 Mc (maleimidocaproyl) LP2 (chemical name mc-3377)
ADC-W-493 Anti-CD19-Mc-MMAF ADC-3 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
CAT# Product Name Linker Payload
ADC-W-2544 Anti-CD44 (Bivatuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2591 Anti-EGFR (Cetuximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2600 Anti-GPNMB (Glembatumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2579 Anti-CEACAM5-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2585 Anti-EGFR (Zalutumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.